Celltrion's Herzuma receives sales approval in Canada - (The Investor via NewsPoints Desk)

  • Celltrion announced that Canadian authorities have authorised the biosimilar Herzuma, The Korea Herald reported Tuesday.

  • In its approval, Health Canada determined that Herzuma's safety and effectiveness are comparable to those of Roche's Herceptin.

  • "With the recent approval for Herzuma, three of Celltrion's antibody biosimilar products have received sales approval in the US and Canada," a Celltrion official stated, adding "we will do our best to provide high-quality products for patients in North America."

  • Herzuma is partnered with Teva in North America.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.